Table 3.

Demographics of patients with regional recurrence outside CTVn.

No.	Sex, age, smoking	Subsite	Stage	Treatment	Failure type	Time to recurrence	Elective levels irradiated	Regional recurrence
1	Male, 46 y, former, multifocal	Piriform sinus (R) Supraglottis (L) Esophagus (mid) Oropharynx (R)	Tis T3N0 T2 Tis	70 Gy (50 Gy) + cisplatin	N+M	5 years and 2 months	Ipsi (R): Ib, II–IVa+b, Vc, VI, VIIa+b; Contra (L): II–IVa+b, Vc, VI, VIIa+b	Ipsi (R): Ib, II, V, VIIa Contra (L): Ib, II, VIIa
2	Male, 63 y, current, multifocal	1. Floor of mouth (L) 2. Tongue (R) 3. Supraglottis 4. Glottis	T2 T2N2b(R) T1 T1	72 Gy (46.4 Gy) + cisplatin	T+N+M	1 year and 6 months	Ipsi (R): Ib, II–IVa, V, VIIb Contra (L): Ib, II–IVa	Contra (L): II–III
3	Male, 67 y, former	Piriform sinus	T3N2b	72 Gy (40 Gy) + cisplatin	N+M	4 months	Ipsi: Ib, II–IVa, V, VIa+b, VIIa+b Contra: II–IVa, VIa+b, VIIa	Contra: II
4	Male, 68 y, current	Piriform sinus	T4aN2b	72 Gy (40 Gy) + cisplatin	T+N	7 months	Ipsi: II–IVa, V, VIIa+b Contra: II–III	Ipsi: VIIa-b
5	Female, 75 y, former	Piriform sinus	T2N2b	72 Gy (40 Gy)	N	4 months	Ipsi: II–IVa, V Contra: II–III	Ipsi: VIIa

Four patients had a recurrence in CTVe, of which one (patient 1) also had a recurrence outside the irradiated volume (ipsilateral level V). One patient had an isolated regional recurrence outside the elective target volume (patient 5, ipsilateral retropharyngeal adenopathy). Dose in brackets shows dose to CTVe. TNM classification according to TNM7.

Contra, contralateral; CTVe, elective clinical target volume; Ipsi, ipsilateral; L, left; N, nodal classification; R, right; T, tumor classification; y, years; M, metastasis.